

Summerset Group

OUTPERFORM

3Q19 Springs Into Action

Summerset Group (SUM) reported its 3Q19 unit sales which were up +11.5% underpinned by strong resales up +33% versus 3Q18 and it has signalled that demand remains robust and vacancy low. SUM is on track to hit our FY19 sales expectations and we have not changed our forecasts or target price. Our rating remains OUTPERFORM.

Resales volumes very positive as occupancy remains high

Resales volumes in 3Q19 were 88 units, up considerably on the 66 units in 3Q18, with SUM maintaining solid occupancy rates across its villages resulting in little vacant resales stock. This was SUM's strongest quarter for resales in two years. SUM's YTD resales volume is 75% of our FY19 forecast resales of 308 units indicating SUM is on track in FY19.

New sales broadly in line but requires elevated 4Q19

SUM sold 77 new units in 3Q19, in line with 82 in the pcp. This is slightly below our forecast run rate for FY19 new sales of 333 units, although SUM noted that presales for its three new villages have been strong supporting a lift in 4Q19. The 4Q is historically a strong sales period and this year it is helped by the timing of new stock. We require new sales of 120 units to hit our FY19 forecast, compared with the average 4Q sales over the last three years of 109 units.

No FY19 earnings guidance comments – development on track

The existing development guidance is 350 new units which implies a very busy 2H19. The near-term development focus is the remaining independent living units at Rototuna (Hamilton), Casebrook (Christchurch), Ellerslie (Auckland) and at its new villages at Kenepuru (Wellington), Richmond (Nelson) and Avonhead (Christchurch). The next news is likely the Environment Court decision on Lower Hutt which is expected shortly.

Aussie a new area of growth

SUM's large pipeline was inflated by the recent acquisition of its first Australian site in Melbourne raising its pipeline to 5,078 units. This move was well signalled and in line with its strategic direction, and we expect SUM to benefit from the high demand for an integrated full continuum of care village offering.

Figure 1. Quarterly Sales track

	3Q18	4Q18	FY18	1Q19	2Q19	3Q19	chg % yoy	% 3Q 2019 YTD Actual	%FY19 Achieved	FY19
New sales	82	112	339	71	65	77	-6.1%	213	64.0%	333
Resales	66	81	301	66	76	88	33.3%	230	74.7%	308
Total	148	193	640	137	141	165	11.5%	443	69.1%	641


Source: Forsyth Barr analysis, Company Reports

Investment View

SUM continues to strengthen its development and operational track record and has a land bank of over six years. There remains significant long-term growth potential from demographic trends and SUM has the expertise to capitalise on these themes. Execution risk is increasing near-term as it tackles large and intensive Auckland developments late in the cycle but the business remains very well placed over the longer term. At current pricing SUM is getting very little credit for its operational and development track record since listing. OUTPERFORM.

NZX Code	SUM
Share price	NZ\$6.50
Target price	NZ\$7.20
Risk rating	High
Issued shares	225.8m
Market cap	NZ\$1,467m
Average daily turnover	335.2k (NZ\$2,009k)

Share Price Performance



Financials: December	18A	19E	20E	21E
NPAT* (NZ\$m)	98.8	102.1	117.5	134.3
EPS* (NZc)	43.9	45.2	52.1	59.5
EPS growth* (%)	19.7	3.0	15.1	14.3
DPS (NZc)	13.2	13.6	15.6	17.9
Imputation (%)	0	0	0	0

Valuation (x)	18A	19E	20E	21E
EV/EBITDA	7.9	15.7	13.8	12.1
EV/EBIT	8.2	16.6	14.6	12.8
PE	14.8	14.4	12.5	10.9
Price / NTA	1.5	1.4	1.3	1.2
Cash dividend yield (%)	2.0	2.1	2.4	2.7
Gross dividend yield (%)	2.0	2.1	2.4	2.7

*Historic and forecast numbers based on underlying profits

Jeremy Simpson, CFA

jeremy.simpson@forsythbarr.co.nz

+64 9 368 0022

Summerset Group Holdings (SUM)

Priced as at 09 Oct 2019: NZ\$6.50

December year end

Forsyth Barr valuation		Valuation Ratios		2017A	2018A	2019E	2020E	2021E			
Valuation methodology	DCF	EV/EBITDA (x)	18.1	7.9	15.7	13.8	12.1				
		EV/EBIT (x)	19.0	8.2	16.6	14.6	12.8				
12-month target price (NZ\$)*	7.20	Spot valuations (NZ\$)	PE (x)	17.7	14.8	14.4	12.5	10.9			
Expected share price return	10.8%	1. DCF	6.70	Price/NTA (x)	1.9	1.5	1.4	1.3			
Net dividend yield	2.4%	2. n/a	n/a	Free cash flow yield (%)	-4.3	-5.6	1.2	1.7			
Estimated 12-month return	13.1%	3. n/a	n/a	Net dividend yield (%)	1.7	2.0	2.1	2.4			
				Gross dividend yield (%)	1.7	2.0	2.1	2.4			
Key WACC assumptions		DCF valuation summary (NZ\$m)		Imputation (%)	0	0	0	0			
Risk free rate	2.00%	Total firm value	1,997	Pay-out ratio (%)	30	30	30	30			
Equity beta	0.88	(Net debt)/cash	(444)								
WACC	7.7%	Value of equity	1,553	Capital Structure	2017A	2018A	2019E	2020E	2021E		
Terminal growth	1.5%	Shares (m)	226	Interest cover EBIT (x)	8.4	9.3	8.3	8.6	8.9		
				Interest cover EBITDA (x)	8.5	20.2	9.3	9.6	9.8		
Profit and Loss Account (NZ\$m)	2017A	2018A	2019E	2020E	2021E						
Sales revenue	186	347	247	283	321	Net debt/ND+E (%)	30.2	31.3	30.8		
Normalised EBITDA	98	234	122	140	159	Net debt/EBITDA (x)	3.5	1.9	3.8		
Depreciation and amortisation	(5)	(7)	(7)	(8)	(9)						
Normalised EBIT	93	228	115	132	151	Key Ratios	2017A	2018A	2019E	2020E	2021E
Net interest	(12)	(12)	(13)	(15)	(16)	Return on assets (%)	4.4	3.9	3.6	3.6	3.7
Associate income	-	-	-	-	-	Return on equity (%)	10.4	10.1	9.9	10.7	11.3
Tax	(0)	(2)	-	-	-	Return on funds employed (%)	9.3	8.4	7.7	8.4	9.1
Minority interests	-	-	-	-	-	EBITDA margin (%)	52.5	67.6	49.3	49.4	49.6
Normalised NPAT	82	99	102	118	134	EBIT margin (%)	50.0	65.7	46.6	46.8	47.0
Abnormals/other	158	116	-	-	-	Capex to sales (%)	138.2	82.7	84.6	100.0	106.1
Reported NPAT	240	215	102	118	134	Capex to depreciation (%)	5,564	4,293	3,092	3,742	3,991
Normalised EPS (cps)	36.7	43.9	45.2	52.1	59.5						
DPS (cps)	11.0	13.2	13.6	15.6	17.9	Operating Performance	2017A	2018A	2019E	2020E	2021E
						Revenue (NZ\$m)					
Growth Rates	2017A	2018A	2019E	2020E	2021E	Care fees	75	91	105	118	131
Revenue (%)	32.6	86.2	-28.7	14.2	13.5	Management fees	36	46	52	62	74
EBITDA (%)	40.9	>100	-47.9	14.4	14.0	Other	0	0	-	-	-
EBIT (%)	41.7	>100	-49.4	14.6	14.0	Fair value m'ment in Investment Property (NZ\$m)					
Normalised NPAT (%)	44.2	21.0	3.4	15.1	14.3	Realised	76	92	90	102	116
Normalised EPS (%)	42.8	19.7	3.0	15.1	14.3	Unrealised	-	117	-	-	-
DPS (%)	42.9	20.0	2.8	15.1	14.3	Total revenue	186	347	247	283	321
Cash Flow (NZ\$m)	2017A	2018A	2019E	2020E	2021E	Key Drivers					
EBITDA	98	234	122	140	159	Sales - new units	382	339	333	400	480
Working capital change	110	(17)	118	183	241	Ave unit price - new sales (NZ\$000s)	488	566	623	635	648
Interest & tax paid	(13)	(13)	(13)	(15)	(16)	Sales - resold units	300	301	308	361	418
Other	0	-	-	-	-	Ave unit price - resales (NZ\$000s)	383	406	438	460	483
Operating cash flow	195	204	227	308	384	Gross development margin (%)	27.3	33.2	28.0	25.0	23.0
Capital expenditure	(257)	(287)	(209)	(283)	(340)	Gross resales margin (%)	21.7	23.5	24.0	23.0	22.0
(Acquisitions)/divestments	-	-	-	-	-	New apartments/units	450	454	350	500	600
Other	-	-	-	-	-	New beds	56	52	80	80	80
Funding available/(required)	(62)	(83)	18	26	44	Portfolio					
Dividends paid	(12)	(18)	(31)	(35)	(40)	Apartments/units	3,278	3,732	4,082	4,582	5,182
Equity raised/(returned)	-	-	-	-	-	Beds	793	845	925	1,005	1,085
Increase/(decrease) in net debt	75	100	13	10	(3)						
Balance Sheet (NZ\$m)	2017A	2018A	2019E	2020E	2021E						
Working capital	(26)	(57)	(48)	(55)	(62)						
Fixed assets	2,193	2,718	3,011	3,387	3,835						
Intangibles	6	7	7	7	7						
Other assets	1	5	5	5	5						
Total funds employed	2,173	2,672	2,974	3,344	3,784						
Net debt/(cash)	340	445	458	468	465						
Other non current liabilities	1,048	1,248	1,487	1,780	2,135						
Shareholder's funds	786	979	1,028	1,096	1,184						
Minority interests	-	-	-	-	-						
Total funding sources	2,173	2,672	2,974	3,344	3,784						

* Forsyth Barr target prices reflect valuation rolled forward at cost of equity less the next 12-months dividend

Investment summary

With a strengthening development and sales track record, and a land bank of circa seven years, Summerset Group (SUM) has delivered to its 450 unit FY18 new build target. There remains significant growth potential from demographic trends, a further lift in its build rate and expansion into Australia with the acquisition of its first site in Victoria.

Business quality

- **Positive demographic trends:** SUM has the expertise to leverage the ageing population and growing popularity of retirement village living.
- **Growing development track record:** SUM built 450 units in FY18, and has achieved attractive development margins recently. Execution is becoming critical as SUM starts building larger high rise developments and increasing project debt.
- **Investing in quality of care:** SUM is investing heavily in its care operation which is increasing the 'needs based' nature of its portfolio and it has started adding dementia services to new developments.

Earnings and cash flow outlook

- **Strong underlying EPS growth track record:** Since listing on the NZX in 2011, SUM has generated strong EPS growth on a consistent basis. A key EPS driver will be SUM lifting its build rate over the medium term from 450 to 600 units per annum and expansion into Australia.
- **Recycling capital:** The occupational right agreement (ORA) structure provides the ability to self-fund development, subsidise the cost of a care facility, recycle capital into new development, and capture capital gains when units are resold.

Company description

SUM is the second largest developer of integrated retirement villages in NZ. It offers a range of lifestyle options and aged care services for the long-stay care of the elderly. At 30 June 2019, it had a portfolio of 3,256 independent units, 615 Serviced and Memory Care apartments and 858 care beds across 24 operating villages. Although its care operations are the smaller part of its business, SUM has increased its focus on aged care services in recent years and continues to invest in this area. SUM was established in 1994 and listed on the NZX in November 2011.


Financial structure

- **Balance sheet:** Gearing has increased as SUM has rapidly lifted its build rate, and invested in higher priced metropolitan land, but debt remains largely project related.
- **Dividends:** SUM has been paying out a dividend at the low end of its 30%–50% target pay-out rate and has a dividend reinvestment plan in place.

Risks factors


- **Oversupply:** The significant industry pipeline poses the threat of short-term oversupply, offset by a likely shortage of quality beds longer term.
- **Housing market downturn:** A downturn in the buoyant housing conditions is a threat to SUM's resales volumes, cash flows, and gearing.

Figure 2. SUM FY18 revenue mix (NZ\$m)



Source: Forsyth Barr analysis, Company Reports

Figure 3. SUM portfolio as at 31 December 2018



Source: Forsyth Barr analysis, Company Reports

Figure 4. Substantial Shareholders

Shareholder	Latest Holding
Harbour Asset Management & Jarden Securities Limited	8.3%
Fisher Funds Management	6.2%


Source: NZX, Forsyth Barr analysis, NOTE: based on SSH notices only

Figure 5. International Compco's


Company	Code	Price	Mkt Cap	PE		EV/EBITDA		EV/EBIT		Cash D/Yld	
<i>(metrics re-weighted to reflect SUM's balance date - December)</i>											
			(m)	2019E	2020E	2019E	2020E	2019E	2020E	2019E	2020E
Summerset Group	SUM NZ	NZ\$6.50	NZ\$1,467	14.4x	12.5x	15.7x	13.7x	16.6x	14.5x	2.4%	
Metlifecare *	MET NZ	NZ\$4.45	NZ\$949	10.5x	10.1x	12.4x	11.9x	13.2x	12.7x	2.6%	
Ryman Healthcare *	RYM NZ	NZ\$12.93	NZ\$6,465	25.9x	22.5x	26.0x	22.6x	28.4x	24.5x	2.2%	
Oceania Healthcare *	OCA NZ	NZ\$1.02	NZ\$622	11.4x	10.4x	12.7x	11.6x	15.0x	13.6x	5.3%	
Arvida Group Limited *	ARV NZ	NZ\$1.46	NZ\$791	14.0x	12.3x	15.6x	12.2x	17.2x	13.4x	4.5%	
Compco Average:				15.4x	13.8x	16.7x	14.6x	18.4x	16.0x	3.7%	
SUM Relative:				-7%	-10%	-6%	-6%	-10%	-10%	-34%	

EV = Current Market Cap + Actual Net Debt

Source: *Forsyth Barr analysis, Bloomberg Consensus, Compco metrics re-weighted to reflect headline (SUM) companies fiscal year end

Figure 6. Consensus EPS Momentum


Source: Forsyth Barr analysis, Bloomberg

Figure 7. 12 Month Forward PE


Source: Forsyth Barr analysis

Not personalised financial advice: The recommendations and opinions in this publication do not take into account your personal financial situation or investment goals. The financial products referred to in this publication may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Adviser. The value of financial products may go up and down and investors may not get back the full (or any) amount invested. Past performance is not necessarily indicative of future performance. Disclosure statements for Forsyth Barr Investment Advisers are available on request and free of charge. **Disclosure:** Forsyth Barr Limited and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) investment banking or other services to, the issuer of those financial products (and may receive fees for so acting). Forsyth Barr is not a registered bank within the meaning of the Reserve Bank of New Zealand Act 1989. Forsyth Barr may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Forsyth Barr confirms no inducement has been accepted from the researched entity, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. **Analyst Disclosure Statement:** In preparing this publication the analyst(s) may or may not have a threshold interest in the financial products referred to in this publication. For these purposes a threshold interest is defined as being a holder of more than \$50,000 in value or 1% of the financial products on issue, whichever is the lesser. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the entity being researched. **Disclaimer:** This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. Forsyth Barr does not make any representation or warranty (express or implied) that the information in this publication is accurate or complete, and, to the maximum extent permitted by law, excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice. Any analyses or valuations will typically be based on numerous assumptions; different assumptions may yield materially different results. Nothing in this publication should be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from doing so, or to engage in any other transaction. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction. **Terms of use:** Copyright Forsyth Barr Limited. You may not redistribute, copy, revise, amend, create a derivative work from, extract data from, or otherwise commercially exploit this publication in any way. By accessing this publication via an electronic platform, you agree that the platform provider may provide Forsyth Barr with information on your readership of the publications available through that platform.